NCT05769075View on ClinicalTrials.gov

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

PHASE1RecruitingINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

October 31, 2025

Conditions
Locally Advanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

TY-2136b

"Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)"

DRUG

TY-2136b

"Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage"

Trial Locations (2)

30322

RECRUITING

Oncology Consultants, Houston

02903

RECRUITING

Rhode Island Hospital, Brown University, Providence

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY